Provider review
HealthRX review: it names the trial, the duration and the figure, and gets all three right
Most sellers quote a weight-loss percentage from nowhere. Some name a trial and then misplace its results by a year. HealthRX does neither. Its semaglutide page says "average 15% body-weight loss at 68 weeks in STEP-1 trial" and its tirzepatide page says "average 21% body-weight loss at 72 weeks in pivotal phase-3 trial". Check both and they hold — right study, right duration, right number, and called an average rather than a promise. That is a low bar that almost nothing clears.
Names the trial, the duration and the figure on both molecules, and all three check out — the most accurate claim set in this month's batch.
Worth trusting if
- You want the study behind the number named, with the duration attached
- You want the figure called an average rather than sold as what you will get
- You want a seller that states what kind of pharmacy makes your medication
Be skeptical if
- You want the pharmacy named rather than described, because this one is not
- You want to check its claim about rival clinics, because it names none of them
- You want a company you can identify — the terms name none
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens healthrx.com. A link is not a recommendation to take anything.
Provenance
What HealthRX actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $190 for a single month; the advertised $99 is a year paid up front.
- Compounded tirzepatide injection — $239 for a single month; $179 a month on a year paid up front.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to HealthRX.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from HealthRX’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“The most-studied GLP-1 compound. Average 15% body-weight loss at 68 weeks in STEP-1 trial. Compounded at a licensed 503A pharmacy. Same price at every dose.”
Read on the HealthRX site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Reported a mean weight reduction of about 15% against about 2% on placebo — the figure and the duration HealthRX quotes.
Three things have to be right for a claim like this to survive, and all three are. The trial is named and it is the correct one for this molecule. The duration is given and it is the real one — 68 weeks, not a compressed six months. And the figure is labeled an average rather than sold as what you will get. Describing semaglutide as the most-studied compound in this class is also fair rather than promotional. The one caveat applies to every compounded product on this site and not to HealthRX in particular: STEP 1 tested the manufacturer's approved semaglutide, and no trial has compared that against a compounded preparation.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Dual-incretin therapy. Average 21% body-weight loss at 72 weeks in pivotal phase-3 trial. Tirzepatide is the active molecule in Zepbound and Mounjaro, a dual GIP and GLP-1 agonist with the largest average weight loss recorded in a phase-3 obesity trial.”
Read on the HealthRX site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. Reported a mean reduction of roughly 21% at the top dose — again the figure and the duration HealthRX quotes.
Same discipline as the semaglutide page and the same result. The duration is correct at 72 weeks, the figure rounds fairly to what the trial reported at the top dose, and it is called an average. The surrounding description is accurate too: tirzepatide is the molecule in Zepbound and Mounjaro, it does act on two receptors, and among approved medicines in this class its trial result is the largest published. HealthRX also scopes that superlative properly, saying in a phase-3 obesity trial rather than claiming a record against everything. As elsewhere, the trial tested the manufacturer's approved product rather than a compounded one.2
Dispensing chain
Who actually fills your prescription
Read the full account
HealthRX states the tier and not the name. Every plan says the prescription is filled by a US-licensed pharmacy that makes the drug to order, and the homepage badges it alongside USP-797 — which is the compounding standard for sterile preparations, a description of how a pharmacy is supposed to work rather than a certificate anyone can look up. No pharmacy, address or license number is published, and no clinician is named at any level. Two things partly offset that. Its LegitScript certificate number is printed on the site and resolves to this domain when checked. And its terms say you may direct the prescription to a pharmacy of your own choosing, which is a genuine freedom and one almost nobody here offers.
Read on the HealthRX site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. What HealthRX offers instead of test data is unusually honest arithmetic: a pricing table with a column showing what each plan renews at, renewals that cost less than the first term, and a comparison against other clinics that carries a date and a stated basis while naming none of them. Its LegitScript certificate number is published and resolves to this domain, which proves a certificate was issued rather than anything about what arrives in the box. The USP-797 badge is a standard rather than an accreditation and should not be read as a third-party audit.
Read on the HealthRX site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
HealthRX publishes no list of states and makes no fifty-state claim, checked on September 13, 2026 across the homepage, the pricing page and the terms. Its terms resolve disputes under California law, which says where it would argue rather than where it will ship.
Read the full licensing claim
No operating company is named beyond the brand — the terms choose California law and JAMS arbitration without identifying an entity, a registered address or a state of incorporation. No clinician is named either, though the site does commit to a licensed clinician's review typically within about a day.
Read on the HealthRX site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names STEP 1 for semaglutide and gives the real duration, 68 weeks, alongside the figure.
- It names the tirzepatide phase 3 result at 72 weeks, and the number rounds fairly to what that trial reported.
- Both figures are labeled averages rather than sold as what you will achieve.
Show 7 more
- Its superlative about tirzepatide is properly scoped to phase-3 obesity trials rather than claimed universally.
- It states that the medication is made to order under a prescription, rather than leaving the question open.
- Its LegitScript certificate number is printed on the site and resolves to this domain.
- Its terms let you send the prescription to a pharmacy of your own choosing.
- It publishes what every plan renews at, and renewals cost less than the first term.
- A full refund if a provider does not approve you, stated as part of every plan.
- No FDA warning letter.
- No pharmacy is named — the tier is stated and the facility is not.
- Its USP-797 badge is a compounding standard, not an accreditation anyone can look up.
- No company is named in its terms, which choose California law without identifying an entity.
Show 4 more
- No clinician is named — no prescriber, no medical director, no advisory panel.
- Its comparison against other clinics gives a date and a basis and names none of them.
- Its sermorelin, NAD+ and other products carry no trial reference we could grade.
- The headline price needs a year paid up front, and a single month is $190.
Verdict
The bottom line
If you want to know whether a seller's numbers can be trusted, this is the one to compare the rest against. It names the study, gives the real duration, calls the result an average, and does not stretch it. What it still will not tell you is which pharmacy fills your prescription or which company you are buying from — and those are the two questions we would put to it before ordering.
Opens healthrx.com. A link is not a recommendation to take anything.
Check the claim
HealthRX's semaglutide page:
"The most-studied GLP-1 compound. Average 15% body-weight loss at 68 weeks in STEP-1 trial."
Its tirzepatide page:
"Dual-incretin therapy. Average 21% body-weight loss at 72 weeks in pivotal phase-3 trial."
STEP 1 randomized 1,961 adults and reported a mean reduction of about 15% — at 68 weeks. 1
SURMOUNT-1 randomized 2,539 and reported roughly 21% at the top dose — at 72 weeks. 2
Right study. Right duration. Right figure. Called an average.
Full analysis — 4 more sectionsWhy that's remarkable · The superlative, scoped · What it still won't tell you · One caveat that isn't theirs
Why that's remarkable
It shouldn't be. But here is what the same month produced from other sellers we graded:
- One named these exact two trials and then placed their results at month six.
- Two others promised 18% by week 24 — on a screen you only reach after handing over your home address.
- A fourth published five statistics under a heading reading "clinical data" and sourced none of them.
HealthRX is the control case. It shows the claim is easy to make correctly, which makes everyone else's version a choice.
The superlative, scoped
"…a dual GIP and GLP-1 agonist with the largest average weight loss recorded in a phase-3 obesity trial."
Note the scoping. Not "the largest ever" — the largest recorded in a phase-3 obesity trial, which is accurate for an approved medicine in this class. 2
That is the difference between a claim that survives checking and one that merely sounds impressive.
What it still won't tell you
Two things.
Which pharmacy. HealthRX says the medication is made to order by a US-licensed pharmacy and badges USP-797 — which is the standard sterile compounding is supposed to follow, not a certificate a facility is awarded. No pharmacy name, no address, no license number.
Which company. Its terms choose California law and JAMS arbitration and never identify the business behind the site.
Against that, its LegitScript certificate number is published in the footer and resolves to this domain, and its terms say you may direct the prescription to a pharmacy of your own choosing — a freedom almost nobody in this market offers.
One caveat that isn't theirs
Both trials tested the manufacturers' approved medicines. HealthRX sells compounded versions — made to order, not FDA-approved, never compared with the approved product in a trial.
That is true of nearly every seller on this site. It means the figures describe the molecule, not the particular preparation you would be sent, and no seller's accuracy about the trial can close that gap.
Questions
Frequently asked questions
Are HealthRX's weight-loss numbers accurate?
Yes, on all three things that have to be right. It names the correct trial for each molecule, gives the real duration — 68 weeks for semaglutide, 72 for tirzepatide — and calls the figure an average rather than a promise. It is the most accurate claim set we graded this month.
Is 21% really the largest?
For an approved medicine in this class, yes, and HealthRX scopes the claim properly by saying in a phase-3 obesity trial rather than claiming an outright record. SURMOUNT-1 reported roughly 21% at the top dose over 72 weeks, which is above what semaglutide achieved in STEP 1.
Do those trials apply to compounded medication?
Only in part, and this is true of nearly every seller we review. Both trials tested the manufacturers' approved products, not compounded versions made to order by a pharmacy, and nothing published compares the two. The figures describe the molecule rather than the exact preparation you would receive.
Which pharmacy makes it?
HealthRX doesn't name one. It does say the medication is made to order under a prescription by a US-licensed pharmacy, and badges USP-797 — which is the standard sterile compounding should follow rather than an accreditation you can look up. Its terms do let you send the prescription to a pharmacy of your own choosing.
What does it cost?
A single month of compounded semaglutide bought outright is $190, and the advertised $99 a month is a year paid up front. Unusually, its pricing table also prints what each plan renews at — and the renewals are cheaper than the first term.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- USP-797
- The US Pharmacopeia chapter setting standards for compounding sterile preparations. It describes how a pharmacy should work, and is not a certificate awarded to a named facility.
- 503A
- A pharmacy that makes a drug to order for one named patient with a prescription. What it produces is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality.
Compare
Others selling what HealthRX sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off HealthRX's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 21% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.